Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

RB-340

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Refuge Biotech, UT MD Anderson Cancer Center

Drug class:

PD1 inhibitor, HER2-targeted CAR-T immunotherapy

Related drugs:

‹

HER2-Specific CAR T (0)

HypoSti.CAR-HER2 T (0)

PSCA/MUC1/TGFβ/HER2/Mesothelin/Lewis-Y/GPC3/AXL/EGFR/B7-H3/Claudin18.2-CAR-T cells (0)

SC-CAR4BRAIN (0)

SCRI-huCAR19v1 (0)

SCRI-huCAR19v2 (0)

TGFBeta resistant HER2/EBV-CTLs (0)

pembrolizumab (726)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab (84)

dostarlimab-gxly (42)

cemiplimab-rwlc (29)

zimberelimab (20)

pucotenlimab (12)

cadonilimab (10)

serplulimab (6)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab (4)

geptanolimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

PD-1 knockout engineered T cells (0)

PF-07209960 (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

HER2-Specific CAR T (0)

HypoSti.CAR-HER2 T (0)

PSCA/MUC1/TGFβ/HER2/Mesothelin/Lewis-Y/GPC3/AXL/EGFR/B7-H3/Claudin18.2-CAR-T cells (0)

SC-CAR4BRAIN (0)

SCRI-huCAR19v1 (0)

SCRI-huCAR19v2 (0)

TGFBeta resistant HER2/EBV-CTLs (0)

›